Semaglutide vs Tirzepatide.
Both are once-weekly injectable medicines that act on GLP-1, the gut hormone behind appetite and blood-sugar control. Tirzepatide adds a second hormone target, GIP. In the only head-to-head trial so far, Tirzepatide produced more average weight loss. Which one fits a person is a decision for their prescriber, based on health history, tolerability and coverage.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand names | Ozempic, Wegovy (injection, pill and HD), Rybelsus | Mounjaro, Zepbound |
| How it works | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Online nickname | "GLP-1S" | "GLP-2T" (it is not a GLP-2 drug) |
| How it is taken | Weekly injection; once-daily tablet (Rybelsus, Wegovy pill) | Weekly injection |
| Weight-management label dose steps | Wegovy: 0.25, 0.5, 1, 1.7 and 2.4 mg; Wegovy HD 7.2 mg | Zepbound: 2.5, 5, 7.5, 10, 12.5 and 15 mg |
| SURMOUNT-5 average weight loss, 72 weeks | 13.7% | 20.2% |
| US status | FDA-approved (prescription) | FDA-approved (prescription) |
What the head-to-head trial found
SURMOUNT-5, published in the New England Journal of Medicine in 2025, randomized 751 adults with obesity and without type 2 diabetes to the highest tolerated dose of Tirzepatide (10 or 15 mg) or Semaglutide (1.7 or 2.4 mg) for 72 weeks. Average weight loss was 20.2% with Tirzepatide and 13.7% with Semaglutide. Stomach side effects were the most common with both, and more people stopped Semaglutide because of them (5.6% vs 2.7%).
What has changed since
In March 2026 the FDA approved Wegovy HD, a 7.2 mg Semaglutide injection for adults who have tolerated 2.4 mg; in the STEP UP trials it produced about 20.7% average weight loss over 72 weeks. Semaglutide for weight management also comes as a once-daily Wegovy pill. These were not part of SURMOUNT-5, so the trial does not compare them.
Tracking either one
The things worth logging are the same: the weekly injection day, each titration step and its date, the injection site, supply on hand, and weight and activity over time. If a prescriber switches you from one to the other, log the switch as a new protocol step so the before and after stay readable.
- ACC: SURMOUNT-5, Tirzepatide vs Semaglutide (NEJM, 2025)
- HCPLive: FDA approves Wegovy HD 7.2 mg (March 2026)
- FDA: medications containing Semaglutide
- FDA: unapproved GLP-1 drugs used for weight loss
Common questions.
Which causes more weight loss, Semaglutide or Tirzepatide?
In the SURMOUNT-5 head-to-head trial, Tirzepatide produced 20.2% average weight loss at 72 weeks versus 13.7% for Semaglutide 2.4 mg. Results vary by person, and the higher-dose Wegovy HD 7.2 mg was not part of that trial.
Is Mounjaro the same as Ozempic?
No. Ozempic is Semaglutide, which targets GLP-1. Mounjaro is Tirzepatide, which targets both GIP and GLP-1. Both are weekly injections approved for type 2 diabetes; their weight-management versions are Wegovy and Zepbound.
Is Wegovy the same as Zepbound?
No. Wegovy is Semaglutide and Zepbound is Tirzepatide. Both are FDA-approved for chronic weight management and have different dose steps.
Can you switch from Semaglutide to Tirzepatide?
Only with your prescriber, who sets the starting dose. PRTCL logs the switch as a new protocol step so your history stays in one place.
Is Tirzepatide a GLP-2 drug?
No. "GLP-2T" is online shorthand. Tirzepatide acts on GIP and GLP-1 receptors. GLP-2 is a different hormone with its own, unrelated medicines.
Can PRTCL track Semaglutide and Tirzepatide?
Yes. PRTCL handles weekly schedules, titration history, injection-site rotation, reminders and supply, with weight and activity from Health Connect beside every dose.
Track it in one system.
PRTCL runs peptides, supplements, nutrition and training together, with reminders at the times you set, reconstitution math, site rotation and inventory that counts itself down. Launching on Android and iPhone the same day. Join the waitlist and enter the draw for one of 57 lifetime Premium subscriptions.